Page 18 - Bharat Biotech

One year on

Ravages of last year's lockdown may still affect economy

Nepal gives emergency use approval to Bharat Biotech's Covid-19 vaccine

Nepal's national drug regulatory authority granted emergency use approval to Bharat Biotech's Covaxin, becoming the third country to approve India's indigenously developed Covid-19 vaccine

Vaccinating India: What next?

We must pull out all the stops to win the race against the virus. And trust each other to do the right thing

Clinically tried and tested: Bharat Biotech boss Ella wins Covaxin fight

Covaxin was India's first indigenously developed vaccine to be approved, controversially under "clinical trial mode" in the first week of January

Bharat Biotech's Covaxin gets authorisation for emergency use: V K Paul

So far 1.9 million people in the country have been given Covaxin, of whom 311 showed some side effects

Top headlines: Bharat Biotech's Covaxin off trial, IDBI Bank out of PCA

Saudi Aramco's $44-billion refinery project at Nanar in Ratnagiri has become a bone of contention between the Maharashtra government and the Centre

Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode

Expert panel recommends emergency use authorisation

Bharat Biotech's Covaxin safe, immunises for at least 3 months: Lancet

Probability of side effects from vaccine 10-12%, 6x lower than other shots

India's massive Covid vaccine campaign boosted by PM Modi receiving shot

Almost 21 million shots have been administered in India so far, up from 5.4 million a month ago

10 mn doses from India won't impact poor nations' vaccine access, says UK

UK Vaccine Deployment Minister Nadhim Zahawi has defended a shipment of 10 million doses of Covishield en route from India amid some concerns that it would impact supplies of poorer nations

India Coronavirus Dispatch: New computational tool to track Covid mutations

Parents more ready to send kids to school, trial candidates wonder if they got vaccine or placebo, Antibodies appear faster if exposed to virus earlier-news relevant to India's fight against Covid-19

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

Covaxin shows 81% efficacy in phase-3 trials, says Bharat Biotech

Firm is gearing up to produce 40 million doses a month. Two Bio-safety Level-3 facilities (which can deal with deadly and contagious viruses) have been set up, third is on the way

Covaxin's efficacy shows immense strength of Atmanirbhar Bharat: ICMR chief

Bharat Biotech said that Covaxin had demostrated an interim efficacy of 81 per cent in preventing Covid-19 in late-stage clinical trials

Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

Covaxin demonstrates significant immunogenicity against the rapidly emerging variants, says Bharat Biotech CMD

PM Modi kicks off third phase of vaccination, takes first jab of Covaxin

In the age group of 45-60 years of age around 18,850 got the first dose and more than 128,000 beneficiaries over 60 years of age got the shot on Monday

Healing a weak regulator

Weaknesses in India's drug regulatory regime and the constraints and questionable decisions of the drug regulator could mar the country's reputation in global markets

PM taking indigenous vaccine should remove doubts on side-effects: Vardhan

Prime Minister Narendra Modi taking an indigenously developed COVID-19 vaccine should remove all doubts that people have about its side-effects, Harsh Vardhan said

Chinese hackers targeted Serum, Bharat Biotech, says security firm

Rivals China and India have both sold or gifted Covid-19 shots to many countries. India produces more than 60 per cent of all vaccines sold in the world

Covid vaccination Phase-II: Check if you are eligible to get a shot

If you are above 45 years old and have one of co-morbidities listed by the govt, you could get a coronavirus vaccine in this phase-2 of vaccination drive. Here's the full list of health issues